Evidence map›Paper›PMID 41229720›Full record

ArticleIndian journal of endocrinology and metabolism

Real-World Usage of Once-Daily Oral Semaglutide in Adults with Type 2 Diabetes: Findings from PIONEER REAL India.

Debmalya Sanyal, Banshi Saboo, Sanjeev R Phatak, Prasanna K M Kumar, Debasis Basu, Nikhil Verma, Arjun Nair, Kingshuk Bhattacharjee, Pankaj Aneja, Brij M M Makkar and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian journal of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Debmalya SanyalDepartment of Endocrinology, Ananda Clinic, Kolkata, West Bengal, India.
Banshi SabooDepartment of Diabetology, Diabetes Care and Hormone Clinic, Ahmedabad, Gujarat, India.
Sanjeev R PhatakDepartment of Diabetes and Metabolic Diseases, Vijayratna Diabetes Diagnostic and Treatment Centre, Ahmedabad, Gujarat, India.
Prasanna K M KumarDepartment of Endocrinology and Diabetes, Center for Diabetes and Endocrine Care, Bengaluru, Karnataka, India.
Debasis BasuDepartment of Internal Medicine and Diabetology, Metta Clinic, Kolkata, West Bengal, India.
Nikhil VermaDepartment of Medicine, ESIC Medical College and Hospital, Faridabad, Haryana, India.
Arjun NairDepartment of Medical Affairs and Medical Education, Novo Nordisk India Private Ltd., Bengaluru, Karnataka, India.
Kingshuk BhattacharjeeDepartment of Medical Affairs and Medical Education, Novo Nordisk India Private Ltd., Bengaluru, Karnataka, India.
Pankaj AnejaDepartment of Diabetes and Metabolic Disorders, Naveda Healthcare Centre, Delhi, India.
Brij M M MakkarDepartment of Diabetes and Obesity, Dr Makkar's Diabetes and Obesity Centre, Delhi, India.
Vijay NegalurDepartment of Diabetes and Thyroid Specialities, Synergy Healthcare, Mumbai, India.
Ambrish MithalDepartment of Endocrinology and Diabetes, Max Super Speciality Hospital, Delhi, India.
Ambika G UnnikrishnanDepartment of Endocrinology, Chellaram Diabetes Institute, Pune, Maharashtra, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The PIONEER REAL India study assessed the effectiveness of oral semaglutide in adults with type 2 diabetes (T2D). Methods: This was a 34-44-week, multicenter, non-interventional study in participants who had not previously received injectable glucose-lowering medications and had initiated treatment with oral semaglutide. Change in HbA Results: Of 388 enrolled, 70.1% of participants completed the study. At baseline, the mean age and T2D duration of the study population were 50.1 and 6.3 years; mean HbA Conclusions: Individuals with T2D treated with once-daily oral semaglutide experienced significant reductions in HbA

Indexed as

Body weightglucagon-like peptide-1 receptor agonistglycemic controloral semaglutidereal-world studytype 2 diabetes

Identifiers

PMID41229720
PMCPMC12604836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.